218 related articles for article (PubMed ID: 37434263)
1. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.
Ye J; Wang H; Medina R; Chakraborty S; Sun M; Valenzuela A; Sang X; Zhang Y; Uher O; Zenka J; Pacak K; Zhuang Z
J Exp Clin Cancer Res; 2023 Jul; 42(1):163. PubMed ID: 37434263
[TBL] [Abstract][Full Text] [Related]
2. rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.
Wang H; Medina R; Ye J; Zhang Y; Chakraborty S; Valenzuela A; Uher O; Hadrava Vanova K; Sun M; Sang X; Park DM; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Adv Sci (Weinh); 2024 Apr; 11(14):e2308280. PubMed ID: 38298111
[TBL] [Abstract][Full Text] [Related]
3. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
4. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
[TBL] [Abstract][Full Text] [Related]
5. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Uher O; Caisova V; Padoukova L; Kvardova K; Masakova K; Lencova R; Frejlachova A; Skalickova M; Venhauerova A; Chlastakova A; Hansen P; Chmelar J; Kopecky J; Zhuang Z; Pacak K; Zenka J
Cancer Immunol Immunother; 2021 Nov; 70(11):3303-3312. PubMed ID: 33855601
[TBL] [Abstract][Full Text] [Related]
6. Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.
Uher O; Huynh TT; Zhu B; Horn LA; Caisova V; Hadrava Vanova K; Medina R; Wang H; Palena C; Chmelar J; Zhuang Z; Zenka J; Pacak K
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439097
[TBL] [Abstract][Full Text] [Related]
7. Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Medina R; Wang H; Caisová V; Cui J; Indig IH; Uher O; Ye J; Nwankwo A; Sanchez V; Wu T; Nduom E; Heiss J; Gilbert MR; Terabe M; Ho W; Zenka J; Pacak K; Zhuang Z
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 33709018
[TBL] [Abstract][Full Text] [Related]
8. HCA587 Protein Vaccine Induces Specific Antitumor Immunity Mediated by CD4
Yang W; Zhang W; Wang X; Tan L; Li H; Wu J; Wu Q; Sun W; Chen J; Yin Y
Anticancer Agents Med Chem; 2021; 21(6):738-746. PubMed ID: 32723258
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
Ravindranathan S; Nguyen KG; Kurtz SL; Frazier HN; Smith SG; Koppolu BP; Rajaram N; Zaharoff DA
Breast Cancer Res; 2018 Oct; 20(1):126. PubMed ID: 30348199
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
14. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
15. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
17.
Baniel CC; Heinze CM; Hoefges A; Sumiec EG; Hank JA; Carlson PM; Jin WJ; Patel RB; Sriramaneni RN; Gillies SD; Erbe AK; Schwarz CN; Pieper AA; Rakhmilevich AL; Sondel PM; Morris ZS
Front Immunol; 2020; 11():1610. PubMed ID: 32849544
[TBL] [Abstract][Full Text] [Related]
18. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
Dezfouli S; Hatzinisiriou I; Ralph SJ
Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
[TBL] [Abstract][Full Text] [Related]
19. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
